MARKET NEWS

INmune Bio Reports Positive Preliminary Data from INB03 Phase 1 Clinical Trial
Aquinox Pharmaceuticals & Neoleukin Therapeutics Announce Merger Agreement
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase 3 Study
Eureka Therapeutics Announces Initiation of Phase 1/2 Clinical Trial
Cytel Launches East On Demand Bringing Adaptive Clinical Trial Design Capabilities to Wider Biopharma Audience
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study

  FEATURED EDITORIAL

  COMPANY PROFILE

Gateway Analytical is an innovative analytical laboratory that specializes in providing expert testing services to the pharmaceutical, medical device, and materials science industries. Built with quality as our cornerstone and timeliness, and customer service as our core values, we are able to offer project turnaround in as fast as 24 hours in a GMP-compliant environment. Our new, fully equipped 8,000-sq-ft laboratory space features HEPA-filtered controlled environments, ISO 9001 and ISO 17025 accreditations, specialized sample preparation capabilities, and a dedicated space for handling cytotoxic drug materials. Gateway is able to provide industry leading materials analysis services tailored to support a variety of unique drug development projects. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Co-Processed Excipient for Direct Compression Designed for Orally Disintegrating Tablets

Developing ODTs is a worldwide trend. In recent years, new excipients and excipient blends have enabled manufacturers to produce ODTs using conventional equipment, ie, blenders and tablet presses. One such product is GRANFILLER-D………

MilliporeSigma Acquires BSSN Software to Accelerate Customers’ Digital Transformation in the Lab

MilliporeSigma Acquires BSSN Software to Accelerate Customers’ Digital Transformation in the Lab

MilliporeSigma has acquired BSSN Software, a Darmstadt, Germany-based laboratory informatics company that makes data more readily accessible for ease of integration, collaboration, analysis and…..

Huge Untapped Potential for Rheumatoid Arthritis Treatment by Targeting OX40

Huge Untapped Potential for Rheumatoid Arthritis Treatment by Targeting OX40

A new study led by experts from the University of Tsukuba first published in Annals of the Rheumatic Diseases in July found that OX40-expressing follicular helper T cells contributed to inflammation by regulating……

Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School 

Spring Bank Announces Collaborative Research Agreement with University of Texas Southwestern Medical School 

Spring Bank Pharmaceuticals, Inc. recently announced that it has entered into a research agreement with the University of Texas Southwestern Medical School to evaluate….

Colorcon & TruTag Technologies Enter Development Agreement

Colorcon & TruTag Technologies Enter Development Agreement

Colorcon and TruTag Technologies, Inc. recently announced execution of a development agreement to enable on-dose verification technology for tablets by combining TruTag’s….

Creating Your Secondary Packaging Strategy - Begin With the End in Mind

Creating Your Secondary Packaging Strategy - Begin With the End in Mind

Whether it is meeting the needs of a rapidly aging market, blocking drug counterfeiters, or differentiating your pharmaceutical product in the market, a secondary packaging program is an important factor in………

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 21 – ODT/Fast Dissolve
August 28 – Transdermal/Topical Delivery